<DOC>
	<DOCNO>NCT00717457</DOCNO>
	<brief_summary>This 3-arm study ass efficacy , safety tolerability taspoglutide compare exenatide patient type 2 diabetes mellitus inadequately control metformin , thiazolidinedione combination . Patients randomize receive taspoglutide ( 10mg weekly 10mg weekly 4 week follow 20mg weekly ) exenatide ( 5 microgram twice daily 4 week follow 10 microgram twice daily ) ratio 1:1:1 addition continue prestudy metformin thiazolidinedione either alone combination . The anticipated time study treatment 3+ year , target sample size &gt; 500 individual .</brief_summary>
	<brief_title>A Study Taspoglutide Versus Exenatide Treatment Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin , Thiazolidinedione Combination Both .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>adult patient , 1875 year age ; type 2 diabetes receive metformin and/or pioglitazone rosiglitazone least 12 week ; HbA1c &gt; =7.0 % &lt; =10 % screening ; BMI &gt; =25kg/m2 ( &gt; 23kg/m2 Asians ) &lt; =45kg/m2 screening ; stable weight +/ 5 % least 12 week prior screen . history type 1 diabetes , diabetes result pancreatic injury secondary form diabetes ; history acute metabolic diabetic complication within previous 6 month ; evidence clinically significant diabetic complication ; know proliferative diabetic retinopathy ; myocardial infarction ( MI ) , coronary artery bypass surgery , posttransplantation cardiomyopathy ( PTCM ) stroke within past 6 month ; abnormality clinical laboratory test ECG , preclude safe involvement study judge investigator ; know hemoglobinopathy chronic anemia ; clinically significant gastrointestinal disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>